Malignant pleural mesothelioma (MPM) is a rare cancer that arises from the mesothelial surfaces of the pleural cavity. It is associated with asbestos inhalation, with 70% of cases being associated with documented asbestos exposure. MPM has a poor prognosis and the outlook has not been improved by newer therapeutic interventions. A new approach developed in our lab, focusing on Surgery for Mesothelioma After Radiation Therapy (SMART) showed promising results in a phase I/II clinical trial. We believe that radiation is important to achieving activation of the immune system and may contribute to the benefits observed in patients. The goal of this project was to develop a mouse model to analyze the immunogenic effect of Local Radiation Therapy ...
ABSTRACT: The aim of the present study was to define the point at which mesothelioma T-cell response...
Given the need to improve the efficacy of standard-of-care immunotherapy (anti-CTLA-4 + anti-PD-1) i...
Given the need to improve the efficacy of standard-of-care immunotherapy (anti-CTLA-4 + anti-PD-1) i...
Malignant pleural mesothelioma (MPM) is a rare cancer that arises from the mesothelial surfaces of t...
Malignant pleural mesothelioma (MPM) is a thoracic aggressive cancer caused by asbestos exposure, wh...
Malignant pleural mesothelioma (MPM) is a thoracic aggressive cancer caused by asbestos exposure, wh...
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface, associated...
Malignant mesothelioma (MM) is a cancer with a high mortality rate and limited therapeutic options, ...
Malignant pleural mesothelioma (MPM) is a relatively rare, but highly lethal cancer of the pleural m...
Malignant pleural mesothelioma (MPM) is a rare malignancy of the pleura that is frequently resistant...
textabstractMalignant mesothelioma (MM) is a highly aggressive neoplasm caused by neoplastic transfo...
International audienceGiven the need to improve the efficacy of standard-of-care immunotherapy (anti...
International audienceMalignant mesothelioma (MM), especially its more frequent form, malignant pleu...
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesoth...
The interplay between the immune system and the pleural mesothelium is crucial both for the developm...
ABSTRACT: The aim of the present study was to define the point at which mesothelioma T-cell response...
Given the need to improve the efficacy of standard-of-care immunotherapy (anti-CTLA-4 + anti-PD-1) i...
Given the need to improve the efficacy of standard-of-care immunotherapy (anti-CTLA-4 + anti-PD-1) i...
Malignant pleural mesothelioma (MPM) is a rare cancer that arises from the mesothelial surfaces of t...
Malignant pleural mesothelioma (MPM) is a thoracic aggressive cancer caused by asbestos exposure, wh...
Malignant pleural mesothelioma (MPM) is a thoracic aggressive cancer caused by asbestos exposure, wh...
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface, associated...
Malignant mesothelioma (MM) is a cancer with a high mortality rate and limited therapeutic options, ...
Malignant pleural mesothelioma (MPM) is a relatively rare, but highly lethal cancer of the pleural m...
Malignant pleural mesothelioma (MPM) is a rare malignancy of the pleura that is frequently resistant...
textabstractMalignant mesothelioma (MM) is a highly aggressive neoplasm caused by neoplastic transfo...
International audienceGiven the need to improve the efficacy of standard-of-care immunotherapy (anti...
International audienceMalignant mesothelioma (MM), especially its more frequent form, malignant pleu...
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesoth...
The interplay between the immune system and the pleural mesothelium is crucial both for the developm...
ABSTRACT: The aim of the present study was to define the point at which mesothelioma T-cell response...
Given the need to improve the efficacy of standard-of-care immunotherapy (anti-CTLA-4 + anti-PD-1) i...
Given the need to improve the efficacy of standard-of-care immunotherapy (anti-CTLA-4 + anti-PD-1) i...